ArticleFrontiers in oncology2021

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.

Weiping Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.